Semaphorin-6D Antibodies

Semaphorin-6D (SEMA6D)

Shows growth cone collapsing activity on dorsal root ganglion (DRG) neurons in vitro. May be a stop signal for the DRG neurons in their target areas, and possibly also for other neurons.

May also be involved in the maintenance and remodeling of neuronal connections. .

Gene Information

Human
Gene Name:	SEMA6D
Uniprot:	Q8NFY4
Entrez:	80031

Family

Belongs to:
semaphorin family

Alternative Names

KIAA1479FLJ11598; sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6D; Sema6D; Semaphorin 6D; semaphorin-6D

Molecular Weight

Mass (kDA):
119.872 kDA

Genomic Context

Human
Location:	15q21.1
Sequence:	15; NC_000015.10 (47184089..47774228)

Subcellular Localizations

[Isoform 1]: Cell membrane; Single-pass type I membrane protein.; [Isoform 2]: Cell membrane; Single-pass type I membrane protein.; [Isoform 3]: Cell membrane; Single-pass type I membrane protein.; [Isoform 4]: Cell membrane; Single-pass type I membrane protein.; [Isoform 5]: Cell membrane; Single-pass type I membrane protein.; [Isoform 7]: Cytoplasm.

Diseases

• Nervousness
• Malignant Neoplasms
• Neoplasms
• Cell Transformation, Neoplastic
• Neurodegenerative Disorders
• Ataxia
• Pleural Neoplasms
• Spastic Paraplegia, Hereditary
• Malignant Pleural Mesothelioma
• Neoplasm Invasiveness
• Spastic Paraplegia, Hereditary, Autosomal Recessive
• Carcinogenesis

• Pleural Mesothelioma
• Congenital Heart Defects
• Tumor Angiogenesis
• Paraplegia
• Colorectal Cancer
• Spinal Cord Diseases

Pathways

• Axon Guidance
• Rna Interference
• Protein Phosphorylation
• Neural Tube Closure
• Cell Proliferation
• Cell Migration
• Gastrulation
• Convergent Extension
• Oocyte Maturation
• Localization
• Tube Closure
• Cardiac Chamber Formation
• Cell Motility

• Cell Death
• T Cell Proliferation
• Angiogenesis
• Invasive Growth
• Spinal Cord Development
• Meiosis
• Organ Growth

PTMs

• Phosphorylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/SEMA6D

Boster Bio - Best Uses Of The SEMA6D Marker

Boster Bio provides a SEMA6D-specific SEM6D marking. This marker is designed for scientists, but it can also be used in many other ways. Scientists can submit their results for specific species, species, or applications and receive product credits. Scientists from all over the world can benefit from this marker. Here are some examples. Continue reading for more information.

Boster Bio Anti-SEM6D SEMA6D Marker

Boster Bio has a monoclonal antisemaphorin6D antibody. This antibody targets semaphorin6D (also known by cytoplasmic, semadomain, and transmembrane). The mass of the protein is approximately 119.9 kilodaltons. Human and mouse have orthologs. The Boster Bio anti SEM6D antibody can be used in immunofluorescent assays.

Sema6D, in addition to its function, also associates well with DCs, which indicates that the proteins might mediate late phase interactions. Additionally, this protein may mediate T cell contact with other cell types. Future studies will be required to determine all interactions between the ligands of the Sema-Plex complex. In addition, it is not clear how Sema6D affects the immune system, or how it interacts with Plex proteins.

The expression pattern of Sema6D is similar to that of CD127 during the late phase of the immune response. CD127 expression in early-phase decreases as the T cell selects into a memory pool. Thus, inhibiting late-phase CD127 expression results in impaired T-cell memory. Sema6D inhibits the expression of late-phase CD127 by T cells. This may be due to Abl kinase (a downstream protein of Sema6D).

Applications

The SEMA6D marker protein has many biological applications. It is important in promoting cushion mesenchymal cell migration. It activates Rho by the PLXNA1 - FARP1 pathway. In addition, it helps regulate the level of BMPs. This protein could be used in biomarkers to help patients with cardiovascular disease and diabetes.

The SEMA6D protein is found in cartilage tissues from both rats and humans. Interestingly, this gene is expressed more in healthy cartilage than in OA. It is still not clear what role SEMA6D plays in OA. The study also showed that SEMA6D regulates levels of miR-7. These studies suggest that SEMA6D may play a significant role in the development and maintenance of OA.

SEMA6D is a novel regulator target for BMP Signalling. However, it has also been demonstrated to play a part in the formation AV cushion. This protein is also implicated in cardiac development and repair. Sema6D may be absent from the heart if it is not present. This can cause aortic Arch interruption, persistent transverse truncus arteriosus, or obligatory right ventricular septal defect.

The SEMA6D mark is a gene that identifies a transmembrane Protein in human cells. It has three domains: the TM, the sema and the cytoplasmic. Semaphorin 6D is a transmembrane protein and can function as a signal-transducer through the plexin receptor PLXNA1.

It regulates activation of T cell. It is also a negative regulator for miR-7. It is a critical mediator of both anabolism and catabolism. This protein has many medical applications. The research community is eager to study its role in human diseases. This is how this protein can be used as a biomarker.

Recent research has shown that the SEMA6D marker inhibits p38 in human bone chondrocytes. Its effects on OA were confirmed by immunofluorescence staining. Moreover, overexpression of SEMA6D enhances the expression of COL2A1 in C28/I2 chondrocytes, which are induced to undergo anabolic metabolism.

The SEMA6D pathway is closely related to miR-195 (Sema6D). SEMA6D may be an indicator of poor response to chemotherapy. However, this protein expression is lower in breast cancer patients with tumors HER2-positive. Its expression is also linked to early recurrences. Through its function in cancer cell growth survival, the SEMA6D genes may mediate this chemotherapy response.

Benefits

The SEMA6D Marker may have benefits for cancer therapy. The SEMA6D Gene targets miR195. This signalling pathway regulates chemoresponse by SEMA6D. SEMA6D can be used to direct therapy and other treatments. It may also be useful in determining the response of cancer cell to chemotherapy and other treatments.

Low SEMA6D is associated with poor survival rates for breast cancer. Researchers evaluated cbioportal transcriptomic data from the validation and discovery cohorts. Kaplan-Meier survival analysis was performed on both low-expression and high expression groups. The authors found that low SEMA6D gene expression was associated both with poor survival and early recurrence. Also, lower SEMA6D levels were associated with lower survival rates than those of high-expression females.

The SEMA6D Marker can help to identify patients at risk for developing a disease by screening for the protein. Researchers also found that SEMA4D knockdown had a significant effect on cord forming ability, while SEMA4D expression was not affected. This suggests that SEMA4D may play a role in NRP1 mediated angiogenesis, maturation. However, more research is needed to determine if the SEMA6D Marker has clinical benefits.